Cytarabine

Near Add Your Location

Sorting 15 by

Accepting patients

Cladribine, Cytarabine and Venetoclax for HR-MDS

A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
  • BCL-2 Inhibitor
  • Hypomethylating Agents (HMA)
  • Phase 2
  • Has results

Accepting patients

Venetoclax Plus Intensive Chemotherapy

Phase 1B Study of Venetoclax in Combination With Standard Intensive Chemotherapy With Daunorubicin Plus Cytarabine Followed by High-Dose Cytarabine in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia and Advanced Myelodysplastic Syndrome
  • BCL-2 Inhibitor
  • Chemotherapy
  • Phase 1

Accepting patients

A Combination of Cladribine, Idarubicin, Cytarabine (CLIA) and Quizartinib for the Treatment of Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS))
  • Tyrosine Kinase (TK) Inhibitor
  • Phase 1/2

Accepting patients

Cytarabine Alternating with Decitabine

Phase II Study of Cladribine Plus Low Dose Cytarabine (LDAC) Induction Followed By Consolidation With Cladribine Plus LDAC Alternating With Decitabine in Patients With Untreated Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
  • Hypomethylating Agents (HMA)
  • Phase 2

Accepting patients

Chemotherapy Plus Venetoclax

Phase II Study of Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With AML, HR MDS, or Myeloid Blast Phase of CML
  • BCL-2 Inhibitor
  • Kinase Inhibitor
  • Tyrosine Kinase (TK) Inhibitor
  • Phase 2

Accepting patients

Gemtuzumab as Part of Chemotherapy

A Phase 2 Study of Fludarabine, Cytarabine, Filgrastim-sndz,Gemtuzumab Ozogamicin and Idarubicin in Newly Diagnosed Core Binding Factor Associated Acute Myelogenous Leukemia
  • Antibody Drug Conjugate (ADC)
  • Hypomethylating Agents (HMA)
  • White Blood Cell Stimulant
  • CD33
  • Phase 2

Accepting patients

Heart Protection w/Dexrazoxane During Chemotherapy

Cardioprotection With Dexrazoxane in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS), Myeloid Blast Phase of Chronic Myeloid Leukemia (CML), Ph+ AML, and Myeloid Blast Phase of Myeloproliferative Neoplasms
  • Chemotherapy
  • Phase 2

Accepting patients

Venetoclax w/ Combination Chemotherapy

A Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive AML Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory AML
  • BCL-2 Inhibitor
  • Chemotherapy
  • Phase 1/2

Accepting patients

CPX-351 (VYXEOS)

A Prospective, Single Site, Single-Arm Pilot Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms
  • Allogeneic Stem Cell Transplant
  • Chemotherapy
  • Steroid
  • Phase 2

Accepting patients

PVEK (IMGN632)

Phase 1 Study of FLAG-Ida With Pivekimab Sunirine (PVEK [IMGN632]) for Adults With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
  • Antibody Drug Conjugate (ADC)
  • CD123
  • Phase 1